Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 617 (miR-617) is a small, noncoding RNA of the microRNA family that regulates gene expression post-transcriptionally and, unusually, can also activate gene transcription by binding gene promoters. miR-617 is coded within an intron and has its own promoter region. In cancer biology, particularly oral squamous cell carcinoma, miR-617 is downregulated via promoter hypermethylation. Experimentally, miR-617 upregulates the DDX27 gene by a novel promoter-interacting mechanism, suppresses cell proliferation, and promotes apoptosis. The PI3K/AKT/MTOR signaling pathway is modulated downstream of the miR-617/DDX27 axis. Advances in understanding its pathway have highlighted miR-617 and its mimics as promising therapeutic targets and potential biomarkers for cancer, though specificity and therapeutic delivery remain significant challenges.
Gene reactivation via promoter hypomethylation (e.g., 5-Azacytidine upregulates miR-617 by demethylating its promoter); miRNA mimic action (synthetic miRNAs can restore or modulate biological functions; for miR-617, mimics demonstrate anti-proliferative and pro-apoptotic effects in OSCC)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 617 (miR-617).